Navigation Links
Cord Blood America to Hold Conference Call on Thursday May 21st at 11 a.m. Eastern Time to Discuss 2009 First Quarter Results and Corporate Developments
Date:5/19/2009

me statements made in this press release are forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We use words such as "anticipate," "believe," "expect," "future," "intend," "plan," and similar expressions to identify forward-looking statements. These statements including those related to the growth of the industry, new stem cell treatments, and the Company's performance, are only predictions and are subject to certain risks, uncertainties and assumptions. Additional risks are identified and described in the Company's public filings with the Securities and Exchange Commission. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company's past performance is not necessarily indicative of its future performance. The Company does not undertake, and the Company specifically disclaims any obligation to update any forward-looking statements to reflect occurrences, developments, events, or circumstances after the date of such statement.

            CONTACT:
            Paul Knopick
            E & E Communications
            949/707-5365
            pknopick@eandecommunications.com


'/>"/>
SOURCE Cord Blood America, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials
2. Study Supports Use of GlycoMark Blood Test to Evaluate Therapy in Children with Diabetes
3. New Licence for Cubicin(R) (daptomycin), the First in a Novel Class of Antibiotic, is Announced Today for the Treatment of Serious Bloodstream and Heart Infections Caused by the Most Problematic UK Organisms, Including MRSA
4. The International Diabetes Federation (IDF) Recommends Tighter Control of Blood Glucose Levels After Meals in People With Diabetes
5. CDC Awards NATT Funding to Improve Blood Clot Awareness
6. FDA Clears OmniWave(TM) Endovascular System for Clot Removal in Peripheral Blood Vessels
7. Cellestis Receives FDA Approval for Blood Test for Detecting Tuberculosis
8. Blood Donations in U.S. Testing Positive for Chagas Disease
9. One of Nations Oldest Blood Services Providers Turns to Sysmex America
10. ExonHit Completes a Prototype to Detect Alzheimers Disease From Blood
11. AspenBio Pharma Pursues FDA 510(k) Application Pathway for Appendicitis Blood Test

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...FirstCall/--ArdeaBiosciences,Inc.(Nasdaq: RDEA )an...chiefexecutiveofficer,willpresentatthePiperJaffray...tailsareasfollows:,PiperJaffray21stAnnualHealthCa...p.m.EasternTime,Location:TheNewYorkPalaceHotel,New...t/ireye/,target=,_blank,title=,http://www.corpora...
(Date:11/24/2009)...ewswire/--Twomoreprestigiousuniversitieshavejoined...dcareerssiteforlifescienceprofessionals. ,, Nor...bboard,joining28othermajorlifesciencetrainingInsti...m ,isonlyforpost-graduatesinthelifesciences.Whilet...et,BioCareerCenteristheonlyonethatserveslifescienc...
(Date:11/24/2009)...4/PRNewswire-FirstCall/--deCODE,genetics,Inc.(Nasd...stday"motionsbytheU.S.BankruptcyCourtfortheDistric...iledavoluntarypetitionfor,reliefunderChapter11ofth.... , TheordersissuedbytheBankruptcyCourtallowt...hapter11proceedings.Inparticular,the,companyreceiv...
(Date:11/24/2009)...ecently approved the Promega PowerPlex 16 HS Syste...rating DNA records for the National DNA Index Syst...WEB) -- The FBI recently approved the Promega Pow...participating in, or generating DNA records for, t...y contains more than seven million profiles and ha...
Breaking Biology Technology:Ardea Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference 2Two Major Universities Join Nation's Leading Postgrad Bio Job Board 2deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 2deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 3NDIS Approval of Promega PowerPlex Kit Clears Path for More DNA Profiles to be Added to U.S. Database 2
...ta Green, a Project Which Will Leverage Rosetta Ge...ng IP Position to Develop a Wide ...s Recently Secured Up to $1.5M From Private Invest...renches as Certain Milestones are ...fied microRNAs Correlated With Algal Oil Content ...
...howed Patients Experienced Improvements in Quality...th Other Anti-TNFs or Methotrexate, SAN FRANCISCO... that patients receiving every four week subcutane...0 mg, an investigational therapy,experienced signi...elated,quality of life (HRQOL) and fatigue. The da...
... Oct. 27 /Xinhua-PRNewswire-FirstCall/ -- Tianyin,...cturer and supplier of,modernized traditional Chin... announced that the Company will present at the Ro... on Tuesday, November 11th, 2008. The,Conference w...ce Hotel in,New York City., The Company,s present...
Other Biology Technology:Rosetta Genomics Leverages its MicroRNA Platform Technologies to Launch Plant Biotech Initiative 2Rosetta Genomics Leverages its MicroRNA Platform Technologies to Launch Plant Biotech Initiative 3Rosetta Genomics Leverages its MicroRNA Platform Technologies to Launch Plant Biotech Initiative 4Golimumab Phase 3 Data Show Significant Improvement In Physical Function In Patients with Rheumatoid Arthritis 2Golimumab Phase 3 Data Show Significant Improvement In Physical Function In Patients with Rheumatoid Arthritis 3Golimumab Phase 3 Data Show Significant Improvement In Physical Function In Patients with Rheumatoid Arthritis 4Golimumab Phase 3 Data Show Significant Improvement In Physical Function In Patients with Rheumatoid Arthritis 5Golimumab Phase 3 Data Show Significant Improvement In Physical Function In Patients with Rheumatoid Arthritis 6Golimumab Phase 3 Data Show Significant Improvement In Physical Function In Patients with Rheumatoid Arthritis 7Golimumab Phase 3 Data Show Significant Improvement In Physical Function In Patients with Rheumatoid Arthritis 8Golimumab Phase 3 Data Show Significant Improvement In Physical Function In Patients with Rheumatoid Arthritis 9Tianyin Pharmaceutical Co., Inc. to Present at Rodman & Renshaw Annual Global Investment Conference in New York City on November 11, 2008 at 12:00 p.m. EST 2Tianyin Pharmaceutical Co., Inc. to Present at Rodman & Renshaw Annual Global Investment Conference in New York City on November 11, 2008 at 12:00 p.m. EST 3
(Date:11/26/2009)...cillin-resistant Staphylococcus Aureus ) and othe...as low-temperature plasma prototype devices have b...ling bactericidal cocktails. , Two prototype dev...ection of healthy skin (e.g. hands and feet) in ho...a lethal threat; and another to shoot bacteria-kil...
(Date:11/25/2009)...r 11, firefighters, police officers and ambulance ...rld Trade Center complex. They battled to save peo...survivors, tackled fires and evacuated as many peo...timated 17,000 people. And making their jobs even ...ghtened workers and their relatives jammed mobile ...
(Date:11/25/2009)...ate University assistant professors recently recei...NSF) to continue research beneficial to understand...00. , Christopher Blackwood, assistant professor...rded grants to support two separate research proje...ter Decomposer Communities and Functions from the ...
Breaking Biology News(10 mins):Plasma produces KO cocktail for MRSA 2Plasma produces KO cocktail for MRSA 3Magic box for mission impossible 2Magic box for mission impossible 3Kent State University professors focus research on the environment with grants totaling $890,000 2Reportlinker Adds Therapeutics for Memory and Cognition Disorders Report 56193 1Reportlinker Adds Therapeutics for Memory and Cognition Disorders Report 56193 2Reportlinker Adds Therapeutics for Memory and Cognition Disorders Report 56193 3Reportlinker Adds Therapeutics for Memory and Cognition Disorders Report 56193 4Reportlinker Adds Therapeutics for Memory and Cognition Disorders Report 56193 5Reportlinker Adds Therapeutics for Memory and Cognition Disorders Report 56193 6Reportlinker Adds Therapeutics for Memory and Cognition Disorders Report 56193 7Reportlinker Adds Therapeutics for Memory and Cognition Disorders Report 56193 8Reportlinker Adds Therapeutics for Memory and Cognition Disorders Report 56193 9Is it Exam Time for Students Already 3F 56191 1Is it Exam Time for Students Already 3F 56191 2Is it Exam Time for Students Already 3F 56191 3Is it Exam Time for Students Already 3F 56191 4Is it Exam Time for Students Already 3F 56191 5Adamas Pharmaceuticals to Present Data on Triple Combination Antiviral Drug Therapy for Drug Resistant Influenza at 2009 ICAAC Annual Meeting 13842 1Adamas Pharmaceuticals to Present Data on Triple Combination Antiviral Drug Therapy for Drug Resistant Influenza at 2009 ICAAC Annual Meeting 13842 2
... research shows that certain genes can influence a...es, cancer for example. New research at the Masoni...tes that genetic markers may also show a person,s ...rch study led by Brian Van Ness, Ph.D., has succes... with early clinical relapse of multiple myeloma, ...
...LE, Ariz. Oct. 21, 2008 TGen has spun off its th...medical information source for oncologists. , The...on a variety of data sources, including genetic-ba...-based Translational Genomics Research Institute. ...e oncologists with the knowledge they need to desi...
...zambiquein response to the urgent need to reduce t... Council for Science (ICSU) has launched a new, 10...o address the gaps in the knowledge and methods th...ence to averting disasters and reducing risk. The ...eral Assembly in Maputo, Mozambique. , Each year ...
Other Biology News:U of MN study shows link between gene variations and cancer survival 2TGen spin-off MedTrust Online enables cancer doctors to quickly obtain best-available information 2International Council for Science launches major research program on natural disasters 2
...GFX Purification Kit, 24 reactions. For the genera....Optimized reagents are packaged together for comp...ptimized protocols can be used for performing labe...leotides.Reliable purification using the CyScribe ...
Canine serum from Equitech-Bio
UV-NIR light source for USB2000, HR4000, HR2000+ from Ocean Optics
Mouse Anti-Human SIGIRR Monoclonal Antibody, Unconjugated, Clone 162201 from R&D Systems
Biology Products: